A study to assess safety and effectiveness of the study drug MT-1303 a
A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis
What was tested
Treatment tested
- Amiselimod
What it measured
Main measures
• Total number of monthly MRI Gd-enhanced T1-weighted lesions observed across post-baseline visits (Weeks 8-24)
MRI lesions
Other measures (1)
• Total number of monthly MRI Gd-enhanced T1-weighted lesions observed across all scheduled post-baseline visits (Weeks 4-24)
MRI lesions
Loading reviews and guidelines…
Related trials
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dime
Phase 3 · Not yet recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to
Phase 3 · Recruiting
Still running
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozani
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarker
Phase 4 · Withdrawn
Stopped
- A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Sept 2012